Medicare AdvantageCoverageMedium impact
MA06.025s, Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments
Independence Blue Cross·Pain Management, Psychiatry, Family Medicine +1 more·Pharmacy
Effective date
Jun 5, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated their policy MA06.025s for presumptive and definitive drug testing in substance abuse and pain management treatments. This affects coverage criteria, medical necessity requirements, medical coding, and general guidelines for drug testing procedures.
Action Required
Before June 5, 2026: Billing team and providers must review updated MA06.025s policy for drug testing in substance abuse and pain management. Update billing procedures for coverage criteria, medical necessity documentation, and coding requirements. Verify current drug testing protocols comply with new Medicare Advantage guidelines.